The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Association Between Lipoprotein Particles and Atherosclerotic Events in Nonalcoholic Fatty Liver Disease
Samarth Patel1, Mohammad Bilal Siddiqui2, Jose Hernandez Roman3, Emily Zhang4, Emily Lee4, Steve Shen4, Masoud Faridnia3, Robert J Mintini5, Sherry Boyett5, Michael O Idowu6, Arun J Sanyal1, Velimir A Luketic1, Mohammad Shadab Siddiqui1
Author information
1Division of Gastroenterology and Hepatology, Hunter-Holmes McGuire Veterans Affairs Medical Center, Richmond, Virginia; Division of Gastroenterology and Hepatology, Virginia Commonwealth University Medical Center, Richmond, Virginia.
2Division of Gastroenterology and Hepatology, Virginia Commonwealth University Medical Center, Richmond, Virginia. Electronic address: https://plus.google.com/+mohammad.siddiqui@vcuhealth.org.
3Department of Medicine, Virginia Commonwealth University Medical Center, Richmond, Virginia.
4School of Medicine, Virginia Commonwealth University, Richmond, Virginia.
5Division of Gastroenterology and Hepatology, Virginia Commonwealth University Medical Center, Richmond, Virginia.
6Department of Pathology, Virginia Commonwealth University Medical Center, Richmond, Virginia.
Abstract
Nonalcoholic fatty liver disease (NAFLD), the most common cause of chronic liver disease,1 is independently associated with increased risk of cardiovascular disease (CVD), which is the leading cause of mortality in patients with NAFLD.2 This is likely caused by the centrality of the liver in lipid homeostasis. Prior cross-sectional studies have shown that NAFLD is associated with perturbations in lipid profile and atherogenic lipoprotein subparticles.3 Although statins improve lipid profile and CVD-associated mortality, residual CVD risk has been demonstrated in major statin trials.4,5 A key contributor to this residual risk is the limited ability of the standard lipid profile to precisely quantify atherogenic lipoprotein subparticles, such as small dense low-density lipoprotein (sdLDL), which might confer higher atherogenic risk. There are currently no studies evaluating the longitudinal impact of sdLDL on atherosclerotic events in NAFLD. Thus, we conducted a prospective study in patients with histologically confirmed NAFLD to better define the relationship among NAFLD, residual CVD risk, and sdLDL.